James L Gulley
National Cancer Institute (NCI) · National Cancer Institute, National Institutes of Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James L Gulley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:21 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06066138 · A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNational Cancer Institute (NCI) · recruiting · Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer · principal investigator
- Ph2NCT05445882 · N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate CancerNational Cancer Institute (NCI) · withdrawn · Castration Resistant Prostate Cancer · principal investigator
- N/ANCT05044780 · Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19National Cancer Institute (NCI) · terminated · COVID-19 · principal investigator
- N/ANCT04866810 · The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)National Cancer Institute (NCI) · suspended · Melanoma · principal investigator
- Ph1/Ph2NCT04574583 · Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)National Cancer Institute (NCI) · completed · Metastatic Cancer, Solid Tumors · principal investigator
- N/ANCT04465214 · Mobile Sensor Technologies to Assess General Symptomology of People With CancerNational Cancer Institute (NCI) · completed · Neoplasms, Solid Tumors, Prostate Cancer · principal investigator
- N/ANCT04442425 · Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor PainNational Cancer Institute (NCI) · completed · Cancer, Neoplasms, Solid Tumors · principal investigator
- Ph1/Ph2NCT03493945 · Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)National Cancer Institute (NCI) · completed · Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm · principal investigator
- Ph1/Ph2NCT02933255 · PROSTVAC in Combination With Nivolumab in Men With Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · principal investigator
- Ph1NCT02179515 · Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)National Cancer Institute (NCI) · completed · Lung Cancer, Breast Cancer, Prostate Cancer · principal investigator
- Ph1NCT01519817 · Cancer Vaccine Targeting Brachyury Protein in TumorsNational Cancer Institute (NCI) · completed · Neoplasms, Malignant Solid Tumors, Colon Neoplasms · principal investigator
- Ph1NCT01417546 · NHS-IL12 for Solid TumorsNational Cancer Institute (NCI) · completed · Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, Malignant Mesenchymal Tumor · principal investigator
- Ph3NCT01322490 · A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerBavarian Nordic · completed · Prostate Cancer Metastatic · principal investigator
- Ph1NCT00923741 · Effect of Talactoferrin in Adults With Non-Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT00514072 · Vaccine Therapy in Treating Patients With Stage D0 Prostate CancerKael-GemVax Co., Ltd. · unknown · Prostate Cancer · principal investigator
- Ph2NCT00450619 · 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · principal investigator
- Ph2NCT00179309 · Docetaxel Alone or in Combination With Vaccine to Treat Breast CancerNational Cancer Institute (NCI) · completed · Breast Cancer · principal investigator
- Ph1NCT00113984 · Vaccine and Antibody Treatment of Prostate CancerNational Cancer Institute (NCI) · completed · Prostatic Neoplasms · principal investigator
- Ph1/Ph2NCT00088413 · PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced CancerNational Cancer Institute (NCI) · completed · Adenocarcinoma, Colorectal Cancer, Ovarian Cancer · principal investigator
- Ph1/Ph2NCT00060528 · Sequential Vaccinations in Prostate Cancer PatientsNational Cancer Institute (NCI) · completed · Prostatic Neoplasms · principal investigator
- N/ANCT00026754 · Eligibility Screening for the NIH Intramural Research Program Clinical ProtocolsNational Cancer Institute (NCI) · completed · Breast Cancer, Prostate Cancer, Lung Cancer · principal investigator
- N/ANCT00001503 · Follow-up Protocol for Patients With Cancer/AIDS/Skin DiseaseNational Cancer Institute (NCI) · completed · Melanoma, Ovarian Cancer, Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Basic Research Support for the CCRZICBC011021 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $2,282,526 awarded in 2025Same name and institution; not confirmed by an ID
- Bench to Beside and Back translational immuno-onocology-CuresZIABC012128 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2022 to 2025 · $50 awarded in 2025Same name and institution; not confirmed by an ID
- Cancer ImmunotherapyZIABC010666 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $4,841,882 awarded in 2025Same name and institution; not confirmed by an ID
- Clinical Research Support for the CCRZIDBC011022 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $2,522,792 awarded in 2025Same name and institution; not confirmed by an ID
- Developing Tumor Infiltrating Lymphocyte Therapy for Patients with HIV and CancerZIABC012198 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2025 · $143,907 awarded in 2025Same name and institution; not confirmed by an ID
- Office of Sponsor and Regulatory OversightZIDBC011875 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2025 · $18,493,892 awarded in 2025Same name and institution; not confirmed by an ID
- Office of Translational ResourcesZICBC011933 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $1,201,329 awarded in 2025Same name and institution; not confirmed by an ID
- CCR Office of Training and EducationZIJBC011133 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 · $160,787 awarded in 2024Same name and institution; not confirmed by an ID
- NCI-Alliance immune-related Adverse Events (irAE) Biorepository-CuresZIABC012160 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2023 · $191,131 awarded in 2023Same name and institution; not confirmed by an ID
- T-Cell Receptor Gene Therapy for Human Cancers-CuresZIABC011871 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2021 to 2023 · $33,240 awarded in 2023Same name and institution; not confirmed by an ID
- Cellular TherapyZIABC012067 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2022 · $286,212 awarded in 2022Same name and institution; not confirmed by an ID
- Clinical trials employing cancer vaccine combination therapiesZIABC010945 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2022 · $715,531 awarded in 2022Same name and institution; not confirmed by an ID
- Medical Oncology HIV-AIDS Clinical ResearchZIDBC011683 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2016 to 2021 · $398,401 awarded in 2021Same name and institution; not confirmed by an ID
- Medical Oncology Service Clinical CoreZIDBC011543 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2021 · $2,257,611 awarded in 2021Same name and institution; not confirmed by an ID
- Medical Oncology Fellowship ProgramZIEBC010843 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2015 · $6,114,523 awarded in 2015Same name and institution; not confirmed by an ID
- Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesZ01BC010666 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2005 to 2008 · $517,380 awarded in 2008Same name and institution; not confirmed by an ID
- Clinical trials employing cancer vaccine combination therapiesZ01BC010945 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $517,380 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:21 UTC. The ranking covers the 200 most relevant of 119 PubMed records, and a shared surname and initials can bring in a namesake. All 119 on PubMed
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.J Clin Oncol · 2010769 citationsRCR 17.5
- Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.J Clin Oncol · 2017486 citationsRCR 15.1
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.Lancet Oncol · 2018473 citationsRCR 15.1
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.JAMA Oncol · 2019397 citationsRCR 13.6
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.Clin Cancer Res · 2018362 citationsRCR 11.2
- Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.Clin Cancer Res · 2005282 citationsRCR 5.3
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.Lancet Oncol · 2012271 citationsRCR 6.6
- Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.J Clin Oncol · 2004250 citationsRCR 5.1
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.Lancet Oncol · 2017247 citationsRCR 7.5
- Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.J Immunother Cancer · 2019241 citationsRCR 8.6